Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Velufenacin in Overactive Bladder
NCT05282069Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of velufenacin in overactive bladder (OAB), sponsored by Dong-A ST. Started May 2022; status: completed.
02
Drugs
velufenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05282069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282069.